Friday 6 November 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.

Revenue: +10.6%
EPS: −104.4%
Free cash flow: −69.3%
Total debt: +16.0%

Quarter to September 2026, against a year earlier

248.43 4.50 +1.84%

Follow BIIB

Alert me

Market cap: $36.1B
P/E: 105×
Fwd P/E: 47.4×
Dividend yield: —
F-score: 4/9
Altman Z: 3.13
Beneish M: −2.67
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Biogen Inc. 10-Q filed Oct 30, 2024

Fiscal Q3 2024 · Period ended Sep 30, 2024 · Filed Oct 30, 2024 · accepted 4:31 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov